Santen underlines importance of a holistic approach to glaucoma management and showcases innovations in surgery at EGS 2020
08 December 2020 – Geneva, Switzerland – Santen EMEA is delighted to be taking part in the European Glaucoma Society’s (EGS) 2020 virtual congress. In addition to the presentation of a number of scientific abstracts, Santen will host an international panel of glaucoma experts for Glaucoma management: The next frontier, an online symposium on Saturday 12 December, 17:15-18:00 CET.
The discussions will explore the value of a holistic approach to managing glaucoma with a greater focus on factors such as tolerability, adherence and the day-to-day experiences of patients in addition to intraocular pressure (IOP) measurement. Prof. José María Martínez de la Casa, will also share the latest in glaucoma surgery innovation centering on the role of surgical interventions in the reduction of IOP.
|Welcome||Dr. Karl Mercieca, UK|
|Should we focus on a more holistic management approach||Dr. Andrew Tatham, UK|
|The VISIONARY study: Real-world insights from a cross-country comparison||Prof. Gábor Holló, Hungary|
|What do you expect from glaucoma surgery?||Prof. José María Martínez de la Casa, Spain|
“Strong reductions in IOP are of course important. However, medication side effects that impact patient quality of life can result in poor tolerability, lower adherence and ultimately, less controlled glaucoma. Issues around eye drop administration such as complex regimens or bottle mechanisms can further compound this,” said Andrew Tatham, Consultant Ophthalmic Surgeon, Princess Alexandra Eye Pavilion, Edinburgh, UK. “When medications are not administered effectively or appropriately, this has an impact on the overall efficacy of the management strategy.”
Throughout EGS 2020, the following abstracts will be presented to highlight Santen's ongoing commitment to real-world evidence and investigating the safety, efficacy and tolerability of the company's glaucoma portfolio:
|Lopez-Lopez F., et al.||Treatment of open angle glaucoma or ocular hypertension with preservative-free tafluprost/timolol fixed dose combination in a real-world clinical practice setting: a cross country subanalysis|
|Oddone F., et al.||Treatment of open angle glaucoma or ocular hypertension with preservative-free tafluprost/timolol fixed dose combination in a real-world setting: analysis by diagnostic subgroup and prior treatment at study entry|
|Florent Aptel., et al.||Outcomes of bleb needling in patients with primary open-angle glaucoma implanted with the MicroShunt|
|Isabelle Riss., et al.||Effect of lens status at baseline on surgical outcomes following MicroShunt implantation in patients with primary open-angle glaucoma: a 2-year pooled analysis|
|Julián García-Feijoó., et al.||One-year safety and effectiveness of MicroShunt implantation versus trabeculectomy across five European sites (ENCORE, 005)|
"We are delighted to be participating in EGS's virtual conference and to have the opportunity, despite the challenges posed by COVID-19, to connect with the ophthalmology community,” said Luis Iglesias, Head of Santen EMEA. “By collaborating with an international panel of experts, we hope to bring the patient experience to the forefront of our discussions as we explore the true value of a holistic approach to glaucoma management.”